small molecule

TRULANCE

PLECANATIDE

Loss of exclusivityJune 2034latest FDA-listed patent expiry
CompanySalix PharmaceuticalsView the full company profile on CliffBio

Drug detail

Brand nameTRULANCE
Active ingredientPLECANATIDE
Strength3MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2017
Marketing statusRX

Listed patents

PatentExpiresType
11834521June 2034product
12146003June 2034product
11142549June 2034product
10011637June 2034substance
9616097August 2032product
11319346March 2032product
9925231September 2031product
9610321September 2031use U-2230
9919024September 2031use U-1999
7041786January 2028substance

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TRULANCE patent cliff — loss of exclusivity June 2034 | CliffBio